Compare Sana Biotechnology Inc (SANA) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Visa Inc — how do they compare? Sana Biotechnology Inc trades at $3.74 (market cap $1.13B), while Visa Inc trades at $361.25 (market cap $671.74B). The key difference: Visa Inc is far larger — about 594.5× Sana Biotechnology Inc's market cap, and Visa Inc pays a 0.74% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | V | |
|---|---|---|
Market Cap | $1.13B | $671.74B |
Sector | Health | Financials |
52-Week High | $5.92 | $370.47 |
52-Week Low | $2.68 | $295.52 |
Enterprise Value | $1.05B | $682.32B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Visa (V) trades at $362.82, up 0.42% today, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 and Q2 2026 EPS exceeding expectations. Revenue grew to $40B in 2025, and net income margin remains robust at 50.78%. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, positioning it for future growth in digital payments.
Outlook is positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 17% upside. Risks include competitive fintech threats and regulatory pressures, but Visa's strong cash flow and market dominance support long-term investment appeal. The upcoming Q3 2026 earnings report on April 28, 2026, will be a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
